Bone News and Research

RSS

Southampton scientists create new method to generate bone cells

Scientists at the University of Southampton have created a new method to generate bone cells which could lead to revolutionary bone repair therapies for people with bone fractures or those who need hip replacement surgery due to osteoporosis and osteoarthritis.

12 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire plc, today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US.

10 Feb 2013

High prevalence of total knee replacement revealed

Research highlights the growing use of total knee replacement in the USA among patients with osteoarthritis and the associated healthcare burden.

8 Feb 2013

Patients with low-grade ACL injuries from skiing can heal without surgery

Roughly a quarter of recreational skiers who tear their anterior cruciate ligament (ACL) while hitting the slopes can be successfully treated without surgery, according to a new study.

7 Feb 2013

Chlorhexidine bathing protects vulnerable hospital patients

Bathing hospital patients with chlorhexidine-impregnated washcloths reduces the risk for them acquiring multidrug-resistant organisms and developing bloodsteam infections, show study findings.

7 Feb 2013

Calcium supplements may increase men’s death risk

Men who have a high intake of supplemental calcium may be at an increased risk for cardiovascular disease death, report researchers.

7 Feb 2013

ACL injuries on the rise among young athletes

Until a child's bones have fully matured (in girls, typically by age 14; in boys, age 16), an injury to the anterior cruciate ligament (ACL)-the primary, stabilizing ligament of the knee joint-requires special consideration, treatment and care to ensure appropriate healing and to prevent long-term complications.

7 Feb 2013

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics, Inc. today announced the initiation of two phase I clinical trials of SGN-CD19A, one for patients with B-cell acute lymphoblastic leukemia (ALL) and one for patients with B-cell non-Hodgkin lymphomas.

6 Feb 2013

Researchers examine Kaiser Permanente's obesity prevention interventions in adults and children

Community-based efforts to change the environment are proving to be an effective way of encouraging more physical activity and nutrition among school-age children, according to findings announced today from Kaiser Permanente.

6 Feb 2013

Stanmore receives FDA clearance for Sculptor Robotic Guidance Arm

Stanmore Implants, specialists in the design and manufacture of patient specific and modular orthopaedic implants, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its Sculptor Robotic Guidance Arm for precision implant placement in unicompartmental knee surgery, also known as partial knee resurfacing.

5 Feb 2013

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

New gold nanoparticle can transport powerful radioactive particles directly to tumors

We've all heard that "it's not wise to use a cannon to kill a mosquito." But what if you could focus the cannon's power to concentrate power into a tiny space? In a new study, University of Missouri researchers have demonstrated the ability to harness powerful radioactive particles and direct them toward small cancer tumors while doing negligible damage to healthy organs and tissues.

5 Feb 2013

Children with autism spectrum disorders more likely to have feeding problems

Healthy eating not only promotes growth and development, but also provides important opportunities for children to socialize during meals. A new, comprehensive analysis of feeding behavior in children with autism spectrum disorders (ASD) indicates that these children are five times more likely to have a feeding problem, including extreme tantrums during meals, severe food selectivity and ritualistic mealtime behaviors.

5 Feb 2013

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Company's Phase IIa dose-escalating clinical trial for ALS.

5 Feb 2013

Ultrasound signs can predict Down’s syndrome

Ultrasound markers that can be detected in the second trimester of pregnancy are strongly predictive for Down’s syndrome, show findings from a systematic review and meta-analysis.

4 Feb 2013

Hope against dangerous form of acute lymphoblastic leukemia

After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer-the first time anyone has linked the disease's reemergence to specific genetic anomalies.

4 Feb 2013

Study provides new insight on cancer prevention

Clear communication between cells is essential to every aspect of the body's internal function. But since cells can't talk, or send emails, how do they communicate?

4 Feb 2013

Mcl-1 gene essential for survival of antibody-producing cells

Scientists have identified the gene essential for survival of antibody-producing cells, a finding that could lead to better treatments for diseases where these cells are out of control, such as myeloma and chronic immune disorders.

3 Feb 2013